{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:22:33Z","timestamp":1740108153793,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Integrating moderate hypofractionation to the macroscopic tumor with elective nodal irradiation while sparing the organs at risk (OAR) in chemoradiotherapy of locally advanced non-small-cell lung cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From 2010\u20132018, treatment, patient and tumor characteristics of 138 patients from two radiation therapy centers were assessed. Chemoradiotherapy by intensity-modulated radiation therapy (IMRT) with a\u00a0simultaneous integrated boost (SIB) to the primary tumor and macroscopic lymph node metastases was used.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 124 (90%) patients received concurrent chemotherapy. 106 (76%) patients had UICC (Union for International Cancer Control) stage \u2265IIIB and 21\u00a0(15%) patients had an oligometastatic disease (UICC stage\u00a0IV). Median SIB and elective total dose was 61.6 and 50.4\u202fGy in 28\u00a0fractions, respectively. Furthermore, 64\u00a0patients (46%) had an additional sequential boost to the primary tumor after the SIB-IMRT main series: median 6.6\u202fGy in median 3\u00a0fractions. The median cumulative mean lung dose was 15.6\u202fGy (range 6.2\u201329.5\u202fGy). Median follow-up and radiological follow-up for all patients was 18.0 months (range 0.6\u201386.9) and 16.0 months (range 0.2\u201386.9), respectively. Actuarial local control rates at 1, 2 and 3\u00a0years were 80.4, 68.4 and 57.8%. Median overall survival and progression-free survival was 30.0 months (95% confidence interval [CI] 23.5\u201336.4) and 12.1 months (95% CI 8.2\u201316.0), respectively. Treatment-related toxicity was moderate. Radiation-induced pneumonitis grade\u00a02 and grade\u00a03 occurred in 13 (9.8%) and 3 (2.3%) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Chemoradiotherapy using SIB-IMRT showed promising local tumor control rates and acceptable toxicity in patients with locally advanced and in part oligometastatic lung cancer. The SIB concept, resulting in a\u00a0relatively low mean lung dose, was associated with low numbers of clinically relevant pneumonitis. The overall survival appears promising in the presence of a\u00a0majority of patients with UICC stage \u2265IIIB disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00066-021-01756-7","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T09:08:53Z","timestamp":1615885733000},"page":"405-415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chemoradiotherapy by intensity-modulated radiation therapy with simultaneous integrated boost in locally advanced or oligometastatic non-small-cell lung cancer\u2014a\u00a0two center experience"],"prefix":"10.1007","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2774-7302","authenticated-orcid":false,"given":"Frederick","family":"Mantel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Kleine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Exner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Weick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Str\u00f6hle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00fclent","family":"Polat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"H\u00f6cht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Flentje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"issue":"13","key":"1756_CR1","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","volume":"28","author":"A Auperin","year":"2010","unstructured":"Auperin\u00a0A et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J\u00a0Clin Oncol 28(13):2181\u20132190","journal-title":"J Clin Oncol"},{"issue":"4","key":"1756_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00066-016-0941-8","volume":"192","author":"M Flentje","year":"2016","unstructured":"Flentje\u00a0M et al (2016) GILT\u2014a randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol 192(4):216\u2013222","journal-title":"Strahlenther Onkol"},{"issue":"24","key":"1756_CR3","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia\u00a0SJ et\u00a0al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N\u00a0Engl J Med 379(24):2342\u20132350","journal-title":"N Engl J Med"},{"issue":"20","key":"1756_CR4","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia\u00a0SJ et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N\u00a0Engl J Med 377(20):1919\u20131929","journal-title":"N Engl J Med"},{"issue":"2","key":"1756_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"JD Bradley","year":"2015","unstructured":"Bradley\u00a0JD et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a\u00a0randomised, two-by-two factorial phase 3\u00a0study. Lancet Oncol 16(2):187\u2013199","journal-title":"Lancet Oncol"},{"issue":"1","key":"1756_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijrobp.2005.06.043","volume":"64","author":"P Giraud","year":"2006","unstructured":"Giraud\u00a0P et al (2006) Probability of mediastinal involvement in non-small-cell lung cancer: a\u00a0statistical definition of the clinical target volume for 3\u2011dimensional conformal radiotherapy? Int J Radiat Oncol Biol Phys 64(1):127\u2013135","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1756_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijrobp.2004.12.060","volume":"63","author":"O Chapet","year":"2005","unstructured":"Chapet\u00a0O et al (2005) CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan. Int J Radiat Oncol Biol Phys 63(1):170\u2013178","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1756_CR8","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.ijrobp.2010.07.1977","volume":"81","author":"F-M Kong","year":"2011","unstructured":"Kong\u00a0F\u2011M et al (2011) Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys 81(5):1442\u20131457","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"1756_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer\u00a0EA et\u00a0al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"35","key":"1756_CR10","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1200\/JCO.2007.13.2191","volume":"25","author":"KE Rosenzweig","year":"2007","unstructured":"Rosenzweig\u00a0KE et al (2007) Involved-field radiation therapy for inoperable non small-cell lung cancer. J\u00a0Clin Oncol 25(35):5557\u20135561","journal-title":"J Clin Oncol"},{"issue":"1","key":"1756_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13014-016-0698-3","volume":"11","author":"R Li","year":"2016","unstructured":"Li\u00a0R et al (2016) Involved field radiotherapy (IFRT) versus elective nodal irradiation (ENI) for locally advanced non-small cell lung cancer: a\u00a0meta-analysis of incidence of elective nodal failure (ENF). Radiat Oncol 11(1):124","journal-title":"Radiat Oncol"},{"issue":"4","key":"1756_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","volume":"21","author":"U Nestle","year":"2020","unstructured":"Nestle\u00a0U et al (2020) Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a\u00a0multicentre, open-label, randomised, controlled trial. Lancet Oncol 21(4):581\u2013592. https:\/\/doi.org\/10.1016\/S1470-2045(20)30013-9","journal-title":"Lancet Oncol"},{"issue":"1","key":"1756_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","volume":"127","author":"U Nestle","year":"2018","unstructured":"Nestle\u00a0U et al (2018) ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol 127(1):1\u20135","journal-title":"Radiother Oncol"},{"issue":"3","key":"1756_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.ejcts.2009.04.003","volume":"36","author":"A Bille","year":"2009","unstructured":"Bille\u00a0A et al (2009) Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg 36(3):440\u2013445","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"1756_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13014-019-1259-3","volume":"14","author":"D Wang","year":"2019","unstructured":"Wang\u00a0D et al (2019) Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a\u00a0retrospective study. Radiat Oncol 14(1):106","journal-title":"Radiat Oncol"},{"issue":"21","key":"1756_CR16","doi-asserted-by":"publisher","first-page":"S2465","DOI":"10.21037\/jtd.2018.01.153","volume":"10","author":"MC Roach","year":"2018","unstructured":"Roach\u00a0MC, Bradley\u00a0JD, Robinson\u00a0CG (2018) Optimizing radiation dose and fractionation for the definitive treatment of locally advanced non-small cell lung cancer. J\u00a0Thorac Dis 10(21):S2465\u2013S2473","journal-title":"J Thorac Dis"},{"issue":"7","key":"1756_CR17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1200\/JCO.19.01162","volume":"38","author":"JD Bradley","year":"2020","unstructured":"Bradley\u00a0JD et al (2020) Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J\u00a0Clin Oncol 38(7):706\u2013714. https:\/\/doi.org\/10.1200\/JCO.19.01162","journal-title":"J Clin Oncol"},{"issue":"4","key":"1756_CR18","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.ijrobp.2016.07.022","volume":"96","author":"J Ramroth","year":"2016","unstructured":"Ramroth\u00a0J et al (2016) Dose and fractionation in radiation therapy of curative intent for non-small cell lung cancer: meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys 96(4):736\u2013747","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1756_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2006.09.005","volume":"43","author":"J Belderbos","year":"2007","unstructured":"Belderbos\u00a0J et al (2007) Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 43(1):114\u2013121","journal-title":"Eur J Cancer"},{"issue":"3","key":"1756_CR20","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.ijrobp.2017.10.042","volume":"100","author":"MD Jeter","year":"2018","unstructured":"Jeter\u00a0MD et al (2018) Simultaneous integrated boost for radiation dose escalation to the gross tumor volume with intensity modulated (photon) radiation therapy or intensity modulated proton therapy and concurrent chemotherapy for stage II to III non-small cell lung cancer: a phase 1 study. Int J Radiat Oncol Biol Phys 100(3):730\u2013737","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"1756_CR21","doi-asserted-by":"publisher","first-page":"8364","DOI":"10.1002\/cam4.3446","volume":"9","author":"Q-S Li","year":"2020","unstructured":"Li\u00a0Q\u2011S et al (2020) Simultaneous integrated boost of intensity-modulated radiation therapy to stage II-III non-small cell lung cancer with metastatic lymph nodes. Cancer Med 9(22):8364\u20138372","journal-title":"Cancer Med"},{"key":"1756_CR22","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.radonc.2018.09.019","volume":"131","author":"J van Diessen","year":"2019","unstructured":"van Diessen\u00a0J et al (2019) The acute and late toxicity results of a\u00a0randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). Radiother Oncol 131:166\u2013173","journal-title":"Radiother Oncol"},{"issue":"1","key":"1756_CR23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13014-018-1073-3","volume":"13","author":"L Ma","year":"2018","unstructured":"Ma\u00a0L et al (2018) An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy. Radiat Oncol 13(1):130","journal-title":"Radiat Oncol"},{"issue":"1","key":"1756_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","volume":"35","author":"SG Chun","year":"2017","unstructured":"Chun\u00a0SG et al (2017) Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J\u00a0Clin Oncol 35(1):56\u201362","journal-title":"J Clin Oncol"},{"issue":"2","key":"1756_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00066-017-1229-3","volume":"194","author":"O Roengvoraphoj","year":"2018","unstructured":"Roengvoraphoj\u00a0O et al (2018) Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer. Strahlenther Onkol 194(2):107\u2013115","journal-title":"Strahlenther Onkol"},{"issue":"8","key":"1756_CR26","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00066-018-1418-8","volume":"195","author":"YS Huang","year":"2019","unstructured":"Huang\u00a0YS et al (2019) Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography. Strahlenther Onkol 195(8):707\u2013718","journal-title":"Strahlenther Onkol"},{"issue":"18","key":"1756_CR27","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez\u00a0DR et al (2019) Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a\u00a0multi-institutional, phase II, randomized study. J\u00a0Clin Oncol 37(18):1558\u20131565","journal-title":"J Clin Oncol"},{"issue":"12","key":"1756_CR28","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","volume":"17","author":"DR Gomez","year":"2016","unstructured":"Gomez\u00a0DR et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a\u00a0multicentre, randomised, controlled, phase 2\u00a0study. Lancet Oncol 17(12):1672\u20131682","journal-title":"Lancet Oncol"},{"key":"1756_CR29","first-page":"67","volume":"130","author":"O Arrieta","year":"2019","unstructured":"Arrieta\u00a0O et al (2019) Radical consolidative treatment provides a\u00a0clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: a phase II study. Cancer Treat Res 130:67\u201375","journal-title":"Cancer Treat Res"},{"issue":"1","key":"1756_CR30","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar\u00a0P et al (2018) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 4(1):e173501","journal-title":"JAMA Oncol"},{"key":"1756_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens\u00a0Y et al (2020) Defining oligometastatic disease from a\u00a0radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol 148:157\u2013166","journal-title":"Radiother Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01756-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-021-01756-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01756-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T15:09:14Z","timestamp":1622646554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-021-01756-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,16]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1756"],"URL":"https:\/\/doi.org\/10.1007\/s00066-021-01756-7","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"type":"print","value":"0179-7158"},{"type":"electronic","value":"1439-099X"}],"subject":[],"published":{"date-parts":[[2021,3,16]]},"assertion":[{"value":"8 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F.\u00a0Mantel, E.\u00a0M\u00fcller, P.\u00a0Kleine, M.\u00a0Zimmermann, F.\u00a0Exner, A.\u00a0Richter, S.\u00a0Weick, S.\u00a0Str\u00f6hle, B.\u00a0Polat, S.\u00a0H\u00f6cht and M.\u00a0Flentje declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Ethics Committee of the University of W\u00fcrzburg approved this study (20200210\u00a001).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}